Release Date: 11-Feb-2025
In 2024, Roche’s Lunsumio, a bispecific antibody for lymphoma, generated US$ 77 million in sales, reflecting a 22% increase from approximately US$ 64 million in 2023. The drug’s steady growth highlights its increasing adoption in the treatment of relapsed or refractory follicular lymphoma. As a bispecific antibody, Lunsumio continues to gain traction due to its targeted mechanism and clinical efficacy. Although its sales remain lower compared to Roche’s top-selling bispecific antibodies, the upward trend underscores its expanding market presence and growing role in Roche’s oncology portfolio. Its consistent revenue increase signals a rising demand for innovative lymphoma therapies.
For Global Bispecific Antibodies Report Sample Contact [email protected]